









AMENDMENTS TO THE CLAIMS:

Please amend claims as follows:

1-3. (Canceled).

4. (Currently amended). A compound ~~Malonamide derivative~~ according to claim 4 32, selected from the group consisting of the compounds of formulas Ila, I Ib, I Ic, I Id, I le, I If, I Ig and I Ih,





wherein R^6 , R^7 , R^8 , p , X , Y , R^9 , q are as defined in claim 32 and R^{10} is H or as defined in claim 3;

and the pharmaceutically acceptable derivatives, salts and solvates thereof in claim 32; or a pharmaceutically acceptable salt thereof.

5. (Canceled).
6. (Withdrawn-currently amended) ~~Malonamide derivative according to claim 4~~ The compound according to claim 32 as a medicament.
7. (Withdrawn-currently amended) ~~Malonamide derivative according to claim 4~~ The compound according to claim 32 as a kinase inhibitor.
8. (Withdrawn-currently amended) ~~Malonamide derivative according to claim 7 characterized in that~~ The compound according to claim 7, wherein the kinases are is selected from the group consisting of raf-kinases and VEGFR kinases.
9. (Currently amended) ~~Pharmaceutical composition, characterized in that it contains one or more compounds~~ A pharmaceutical composition, comprising the compound according to claim 4 32 and one or more pharmaceutical ingredients.
10. (Withdrawn-currently amended) Pharmaceutical composition according to claim 9, ~~characterised~~ characterized in that it contains one or more additional compounds other than said compound, selected from the group consisting of physiologically acceptable excipients, auxiliaries, adjuvants, carriers and pharmaceutical active ingredients.
11. (Withdrawn-currently amended) Process for the manufacture of a pharmaceutical composition, ~~characterised~~ characterized in that one or more compounds according to claim 4 32 and one or more compounds, selected from the group consisting of carriers, excipients, auxiliaries and pharmaceutical active ingredients other than the compounds according to

claim 4 32, is processed by mechanical means into a pharmaceutical composition that is suitable as dosage form for application and/or administration to a patient.


12. (Canceled).
13. (Canceled).
14. (Canceled).
15. (Withdrawn-currently amended) ~~Use according to claim 13, characterised in that~~ The method of claim 25, wherein the disorders are caused, mediated and/or propagated by kinases selected from raf-kinases and VEGFR kinases.
16. (Withdrawn-currently amended) ~~Use according to claim 13, characterised in that~~ The method of claim 25, wherein the disorders are selected from the group consisting of hyperproliferative and nonhyperproliferative disorders.
17. (Withdrawn-currently amended) ~~Use according to claim 15, characterised in that~~ The method of claim 16, wherein the disorder is cancer.
18. (Withdrawn-currently amended) ~~Use according to claim 15, characterised in that~~ The method of claim 16, wherein the disorder is noncancerous.
19. (Withdrawn-currently amended) ~~Use according to claim 15, characterised in that~~ The method of claim 18, wherein the noncancerous disorders are selected from the group consisting of psoriasis, arthritis, inflammation, endometriosis, scarring, benign prostatic hyperplasia, immunological

diseases, autoimmune diseases and immunodeficiency diseases.

20. (Withdrawn-currently amended) ~~Use according to claim 15, characterised in that~~ The method of claim 17, wherein the disorders are selected from the group consisting of brain cancer, lung cancer, squamous cell cancer, bladder cancer, gastric cancer, pancreatic cancer, hepatic cancer, renal cancer, colorectal cancer, breast cancer, head cancer, neck cancer, oesophageal cancer, gynaecological cancer, thyroid cancer, lymphoma, chronic leukaemia and acute leukaemia.
21. (Withdrawn-currently amended) ~~Use according to claim 15, characterised in that~~ The method of claim 16, wherein the disorders are selected from the group consisting of arthritis, restenosis; fibrotic disorders; mesangial cell proliferative disorders, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathy syndromes, organ transplant rejection, glomerulopathies, metabolic disorders, inflammation and neurodegenerative diseases.
22. (Withdrawn-currently amended) ~~Use according to claim 15, characterised in that~~ The method of claim 16, wherein the disorders are selected from the group consisting of rheumatoid arthritis, inflammation, autoimmune disease, chronic obstructive pulmonary disease, asthma, inflammatory bowel disease, fibrosis, atherosclerosis, restenosis, vascular disease, cardiovascular disease, inflammation, renal disease and angiogenesis disorders.
23. (Canceled).
24. (Withdrawn-currently amended) ~~Use according to claim 23, characterised in that~~ The method of claim 15, wherein the kinase is one or more raf-

kinases, selected from the group consisting of A-Raf, B-Raf and Raf-1.

25. (Withdrawn-currently amended) ~~Method A method~~ for the treatment and/or prophylaxis of disorders, ~~characterised in that one or more compounds wherein the compound~~ according to claim 4 32 is administered to a patient in need of such a treatment.
26. (Withdrawn-currently amended) ~~Method according to claim 25;~~ ~~characterised in that the one or more compounds are administered as a A~~ method for the treatment and/or prophylaxis of disorders wherein the pharmaceutical composition according to claim 9 is administered.
27. (Canceled).
28. (Withdrawn-currently amended) ~~Method for the treatment according to~~ ~~claim 27, characterised in that the disorders is~~ The method of claim 25, wherein the one or more disorders result from cancerous cell growth mediated by one or more kinases.
29. (Withdrawn-currently amended) ~~Method for producing compounds of~~ ~~formula II, characterised in that A method for producing the compound of~~ claim 32, wherein:
 - a) a compound of formula III




wherein

L^1 is Cl, Br, I, OH, an esterified OH-group or a diazonium moiety, and R^6 , R^7 , R^8 , p , Ar^1 , Y are as defined in claim 32,

is reacted

b) with a compound of formula IV,




wherein

L^2 , L^3 are independently from one another H or a metal ion, and R^9 , q , X , Ar^2 , R^{10} and r are as defined in claim 32,

and optionally

c) isolating and/or treating the compound of formula II obtained by said reaction with an acid, to obtain the salt thereof.


30. (Withdrawn) Compound of formula III,



wherein

L^1 is Cl, Br, I, OH, an esterified OH-group or a diazonium moiety, and R^6 , R^7 , R^8 , p, Ar^1 , Y are as defined in claim 3.


31. (Withdrawn) Compound of formula IV,



wherein

L^2 , L^3 are independently from one another H or a metal ion, and R^9 , q, X, Ar^2 , R^{10} and r are as defined in claim 3.

32. (New) A compound of formula II:



wherein

Ar^1 is phenyl, pyridinyl, oxazolyl, isoxazolyl, pyrazolyl or imidazolyl,

Ar^2 is pyridinyl,

R^{10} is selected from the group consisting of alkyl comprising 1 to 4 carbon atoms, alkoxy comprising 1 to 4 carbon atoms, Hal, CH_2Hal , $CH(Hal)_2$, perhaloalkyl comprising 1 to 4 carbon atoms, NO_2 , $(CH_2)_nCN$, $(CH_2)_nNR^{11}R^{12}$, $(CH_2)_nO(CH_2)_kNR^{11}R^{12}$, $(CH_2)_nCOR^{13}$, $(CH_2)_nCOOR^{13}$, $(CH_2)_nCONR^{11}R^{12}$, $(CH_2)_nSO_2NR^{11}R^{12}$ and $(CH_2)_nS(O)_uR^{13}$,

k is 0, 1 or 2,

r is 0, 1 or 2;

R^6 , R^7 are independently selected from the meanings given for R^8 , R^9 , or R^6 and R^7 together form a carbocyclic residue comprising 3 to 7 carbon atoms or a heterocyclic residue comprising 1, 2 or 3 hetero atoms, selected from the group consisting of O, N and S, and 2 to 6 carbon atoms, said carbocyclic or heterocyclic residue being unsubstituted or comprising 1, 2 or 3 substituents, selected from the meanings given for R^8 , R^9 and R^{10} ,

R^8 , R^9 are independently selected from a group consisting of H, A, cycloalkyl comprising 3 to 7 carbon atoms, Hal, CH_2Hal , $CH(Hal)_2$, $C(Hal)_3$, NO_2 , $(CH_2)_nCN$, $(CH_2)_nNR^{11}R^{12}$, $(CH_2)_nOR^{11}$, $(CH_2)_nO(CH_2)_kNR^{11}R^{12}$, $(CH_2)_nCOOR^{12}$, $(CH_2)_nCONR^{11}R^{12}$, $(CH_2)_nNR^{11}COR^{13}$, $(CH_2)_nNR^{11}CONR^{11}R^{12}$, $(CH_2)_nNR^{11}SO_2A$, $(CH_2)_nSO_2NR^{11}R^{12}$, $(CH_2)_nS(O)_uR^{13}$, $(CH_2)_nOC(O)R^{13}$, $(CH_2)_nCOR^{13}$, $(CH_2)_nSR^{11}$, $CH=N-OA$, $CH_2CH=N-OA$, $(CH_2)_nNHOA$, $(CH_2)_nCH=N-R^{11}$, $(CH_2)_nOC(O)NR^{11}R^{12}$, $(CH_2)_nNR^{11}COOR^{12}$, $(CH_2)_nN(R^{11})CH_2CH_2OR^{13}$,

$(\text{CH}_2)_n\text{N}(\text{R}^{11})\text{CH}_2\text{CH}_2\text{OCF}_3$, $(\text{CH}_2)_n\text{N}(\text{R}^{11})\text{C}(\text{R}^{13})\text{HCOOR}^{12}$,
 $\text{C}(\text{R}^{13})\text{HCOOR}^{12}$, $(\text{CH}_2)_n\text{N}(\text{R}^{11})\text{CH}_2\text{CH}_2\text{N}(\text{R}^{13})\text{CH}_2\text{COOR}^{12}$,
 $(\text{CH}_2)_n\text{N}(\text{R}^{11})\text{CH}_2\text{CH}_2\text{NR}^{11}\text{R}^{12}$, $\text{CH}=\text{CHCOOR}^{11}$,
 $\text{CH}=\text{CHCH}_2\text{NR}^{11}\text{R}^{12}$, $\text{CH}=\text{CHCH}_2\text{NR}^{11}\text{R}^{12}$, $\text{CH}=\text{CHCH}_2\text{OR}^{13}$,
 $(\text{CH}_2)_n\text{N}(\text{COOR}^{11})\text{COOR}^{12}$, $(\text{CH}_2)_n\text{N}(\text{CONH}_2)\text{COOR}^{11}$,
 $(\text{CH}_2)_n\text{N}(\text{CONH}_2)\text{CONH}_2$, $(\text{CH}_2)_n\text{N}(\text{CH}_2\text{COOR}^{11})\text{COOR}^{12}$,
 $(\text{CH}_2)_n\text{N}(\text{CH}_2\text{CONH}_2)\text{COOR}^{11}$, $(\text{CH}_2)_n\text{N}(\text{CH}_2\text{CONH}_2)\text{CONH}_2$,
 $(\text{CH}_2)_n\text{CHR}^{13}\text{COR}^{11}$, $(\text{CH}_2)_n\text{CHR}^{13}\text{COOR}^{11}$,
 $(\text{CH}_2)_n\text{CHR}^{13}\text{CH}_2\text{OR}^{14}$, $(\text{CH}_2)_n\text{OCN}$ and $(\text{CH}_2)_n\text{NCO}$, wherein

R^{11} , R^{12} are independently selected from a group consisting of H, A and
 $(\text{CH}_2)_m\text{Ar}^3$ or in $\text{NR}^{11}\text{R}^{12}$,

R^{11} and R^{12} form, together with the N-Atom they are bound to, a 5-, 6- or
 7-membered heterocyclous which optionally contains 1 or 2
 additional hetero atoms, selected from N, O and S,

R^{13} , R^{14} are independently selected from a group consisting of H, Hal,
 A, $(\text{CH}_2)_m\text{Ar}^4$ and $(\text{CH}_2)_m\text{Het}$,

A is selected from the group consisting of alkyl, alkenyl,
 cycloalkyl, alkylencycloalkyl, alkoxy and alkoxyalkyl,

Ar^3 , Ar^4 are independently from one another aromatic hydrocarbon
 residues having 5 to 12 carbon atoms which are optionally
 substituted by one or more substituents, selected from a group
 consisting of A, Hal, NO_2 , CN, OR^{15} , $\text{NR}^{15}\text{R}^{16}$, COOR^{15} ,
 $\text{CONR}^{15}\text{R}^{16}$, $\text{NR}^{15}\text{COR}^{16}$, $\text{NR}^{15}\text{CONR}^{15}\text{R}^{16}$, $\text{NR}^{16}\text{SO}_2\text{A}$, COR^{15} ,
 $\text{SO}_2\text{R}^{15}\text{R}^{16}$, $\text{S}(\text{O})_u\text{A}$ and OOCR^{15} ,

- Het is a saturated, unsaturated or aromatic heterocyclic residue which is optionally substituted by one or more substituents, selected from a group consisting of A, Hal, NO₂, CN, OR¹⁵, NR¹⁵R¹⁶, COOR¹⁵, CONR¹⁵R¹⁶, NR¹⁵COR¹⁶, NR¹⁵CONR¹⁵R¹⁶, NR¹⁶SO₂A, COR¹⁵, SO₂R¹⁵R¹⁶, S(O)_uA and OOCR¹⁵,
- R¹⁵, R¹⁶ are independently selected from a group consisting of H, A, and (CH₂)_mAr⁶, wherein
- Ar⁶ is a 5- or 6-membered aromatic hydrocarbon which is optionally substituted by one or more substituents selected from a group consisting of methyl, ethyl, propyl, 2-propyl, tert.-butyl, Hal, CN, OH, NH₂ and CF₃,
- m and n are independently of one another 0, 1, 2, 3, 4, or 5,
- X is selected from the group consisting of O, S, NR¹¹, CHOR¹¹, CH₂, CH₂CH₂, OCH₂, CH₂O, OCH₂CH₂, CH₂CH₂O
- h, i are independently from each other 0, 1, 2, 3, 4, 5, or 6, and
- j is 1, 2, 3, 4, 5, or 6,
- Y is selected from O, S, NR²¹, C(R²²)-NO₂, C(R²²)-CN and C(CN)₂, wherein
- R²¹ is independently selected from the meanings given for R¹³, R¹⁴ and
- R²² is independently selected from the meanings given for R¹¹, R¹²,

p is 0, 1, 2, 3, 4 or 5,

q is 0, 1, 2, 3 or 4,


u is 0, 1, 2 or 3,



















and


Hal is independently selected from a group consisting of F, Cl, Br and I;


or a pharmaceutically acceptable salt thereof.

33. (New) A compound according to claim 32, selected from the group consisting of the compounds of formula A-NH-CO-CH₂-CO-NH-B, wherein A and B are as given below:












(27)




(28)




(29)




(30)




(31)




(32)





(33)




(34)









(49)




(50)




(51)




(52)




(53)




(54)




(55)




(56)




(57)





(58)





(59)





(60)





(61)





(62)





(63)





(64)





(65)





(66)





(67)





(68)





(69)




(70)




(71)




(72)




(73)




(74)




(75)





(76)





(77)





(78)





(79)















(109)





(110)




(111)




(112)




(113)




(114)





(115)





























(116)






















































































(180)





(181)





(182)





(183)





(184)





(185)





(186)




(187)




(188)




(189)




(190)





(191)


















(192)

























(193)



































or a pharmaceutically acceptable salt thereof.